Showing results (391-400 of 483) with videos related to
Sort By:
Pageof 49
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.Advances in Therapy|January 21, 2021
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab MonotherapyAjai Chari, Markus Munder, Katja Weisel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.Clinical Lymphoma, Myeloma & Leukemia|December 25, 2022
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease RegistryHans C Lee, Karthik Ramasamy, Katja Weisel, et al.Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.American Journal of Hematology|March 31, 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter AnalysisMaximilian Al-Bazaz, Winfried Alsdorf, Lisa Leypoldt, et al.Mycoses|August 12, 2018
Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)Markus Ruhnke, Gerhard Behre, Dieter Buchheidt, et al.Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.Pageof 49